ADH1B and ALDH Gene Variants and Lung Cancer Risk

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-99
SponsorKaohsiung Medical University

About this trial

Lung cancer in never-smokers is increasingly recognized as a disease influenced by genetic susceptibility. Aldehyde-metabolizing enzymes, including the ALDH gene family and ADH1B, play key roles in detoxifying reactive aldehydes that can damage DNA and promote oxidative stress. In this study, we will examine whether ten selected genetic variants, nine single nucleotide polymorphisms (SNPs) across five ALDH family genes and one variant in ADH1B are associated with the risk of lung cancer and its major subtypes. Limited epidemiological evidence is currently available on the association between these aldehyde-metabolizing gene variants and lung cancer. This research aims to clarify their potential contribution to the development of lung cancer, particularly among never-smokers.

Eligibility criteria

Qualifiers

Incident lung cancer cases confirmed by pathology and healthy adult over age of 18 years.

Disqualifiers

Individuals with incomplete data will not be included as study participants.

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

No trial groups listed

Locations

This trial has no locations

Sponsors and collaborators

Kaohsiung Medical University

Lead sponsor

Kaohsiung Medical University Chung-Ho Memorial Hospital

Sponsor institution